- Home
- TCRX vs IVVD Comparison
TCRX vs IVVD Comparison
Compare TCRX & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- IVVD
- Stock Information
- Founded
- TCRX 2018
- IVVD 2020
- Country
- TCRX United States
- IVVD United States
- Employees
- TCRX N/A
- IVVD N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- IVVD Health Care
- Exchange
- TCRX Nasdaq
- IVVD Nasdaq
- Market Cap
- TCRX 91.7M
- IVVD 96.7M
- IPO Year
- TCRX 2021
- IVVD 2021
- Fundamental
- Price
- TCRX $1.79
- IVVD $0.58
- Analyst Decision
- TCRX Strong Buy
- IVVD Strong Buy
- Analyst Count
- TCRX 6
- IVVD 3
- Target Price
- TCRX $9.50
- IVVD $3.85
- AVG Volume (30 Days)
- TCRX 255.2K
- IVVD 817.4K
- Earning Date
- TCRX 08-12-2025
- IVVD 08-14-2025
- Dividend Yield
- TCRX N/A
- IVVD N/A
- EPS Growth
- TCRX N/A
- IVVD N/A
- EPS
- TCRX N/A
- IVVD N/A
- Revenue
- TCRX $6,961,000.00
- IVVD $46,210,000.00
- Revenue This Year
- TCRX $159.20
- IVVD $345.16
- Revenue Next Year
- TCRX N/A
- IVVD $161.08
- P/E Ratio
- TCRX N/A
- IVVD N/A
- Revenue Growth
- TCRX N/A
- IVVD 1941.08
- 52 Week Low
- TCRX $1.02
- IVVD $0.35
- 52 Week High
- TCRX $6.23
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- TCRX 54.34
- IVVD 32.63
- Support Level
- TCRX $1.60
- IVVD $0.75
- Resistance Level
- TCRX $1.86
- IVVD $0.80
- Average True Range (ATR)
- TCRX 0.10
- IVVD 0.06
- MACD
- TCRX 0.00
- IVVD -0.01
- Stochastic Oscillator
- TCRX 70.37
- IVVD 0.47
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.